Lates News

The Food and Drug Administration (FDA) of the United States has approved the new once-daily oral treatment for HIV-1 infection developed by Merck, known as doravirine/islatravir. This drug is suitable for adult patients whose viral load has been suppressed after receiving antiretroviral therapy.